Physician profile
Samuel Liu
NPI 1912935628
$1,335.89
in general payments reported to CMS, 2019-2025
13 companies · $76.97 in 2025
The $76.97 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $51.77 · 2021: $12.78 · 2022: $444 · 2023: $197 · 2024: $206 · 2025: $76.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.60 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $405.84 | 2019-2024 | Parsabiv, Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $164.00 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $158.82 | 2022-2024 | Lupkynis |
| Allergan, INC. | $145.97 | 2019 | |
| Akebia Therapeutics INC | $143.89 | 2020-2022 | |
| Ardelyx, INC. | $100.25 | 2024 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $69.13 | 2020-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $65.17 | 2019 | |
| Novo Nordisk INC | $23.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.97 | 2023 | Farxiga |
| Johnson & Johnson Surgical Vision, INC. | $12.78 | 2021 | |
| Horizon Therapeutics Plc | $11.80 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.